MCLR TO2 — Medclair Invest AB Share Price
Last trade - 00:00- SEK126.05m
- SEK125.12m
- SEK24.89m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 0.02 | ||
| PEG Ratio (f) | 0 | ||
| EPS Growth (f) | 215.87% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.89 | ||
| Price to Tang. Book | 5.69 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 3.18 | ||
| EV to EBITDA | 26.41 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -2.97% | ||
| Return on Equity | -2.89% | ||
| Operating Margin | -5.02% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | SEKm | 4.89 | 5.31 | 6.33 | 10.69 | 24.89 | 123 | 224 | 44.72% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | +78.26 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Medclair Invest AB is a Sweden-based research and development company engaged in the measurement, collection and destruction of Nitrous Oxide (N2O). The Company works on process gas purification, gas measurement, ventilation, and control and specialized in catalytic gas purification. The Company’s customers are mainly in healthcare areas that require a climate-smart use of Nitrous Oxide for pain relief such as Maternity wards, Children’s healthcare facilities and Dental care facilities.
Directors
- Last Annual
- December 31st, 2022
- Last Interim
- March 31st, 2023
- Incorporated
- January 1st, 1970
- Public Since
- March 3rd, 2017
- Sector
- Machinery, Equipment & Components
- Industry
- Industrials
- Exchange
- Nordic Growth Market - Stockholm
- Shares in Issue
- 82,492,057
- Address
- G-Lab21 Vastra Hamngatan 7C, GOETEBORG, 411 17
- Web
- Phone
- +46 24319090
- Auditors
- Allians Auditeurs & Associes
Similar to MCLR TO2
Abelco Investment AB
Nordic Growth Market - Stockholm
MBRS AB
Nordic Growth Market - Stockholm
Medclair Invest AB
Nordic Growth Market - Stockholm
Rentunder Holding AB
Nordic Growth Market - Stockholm
Sarsys AB
Nordic Growth Market - Stockholm
FAQ
As of Today at 19:14 UTC, shares in Medclair Invest AB are trading at SEK0.01. This share price information is delayed by 15 minutes.
Shares in Medclair Invest AB last closed at SEK0.01 and the price had moved by -97.67% over the past 365 days. In terms of relative price strength the Medclair Invest AB share price has underperformed the FTSE Global All Cap Index by -97.86% over the past year.
There is no consensus recommendation for this security.
Medclair Invest AB does not currently pay a dividend.
Medclair Invest AB does not currently pay a dividend.
Medclair Invest AB does not currently pay a dividend.
To buy shares in Medclair Invest AB you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of SEK0.01, shares in Medclair Invest AB had a market capitalisation of SEK101.30m.
Here are the trading details for Medclair Invest AB:
- Country of listing: Sweden
- Exchange: NGM
- Ticker Symbol: MCLR TO2
Based on an overall assessment of its quality, value and momentum Medclair Invest AB is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Medclair Invest AB. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -88.04%.
As of the last closing price of SEK0.01, shares in Medclair Invest AB were trading -93.7% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Medclair Invest AB PE ratio based on its reported earnings over the past 12 months is 0.02. The shares last closed at SEK0.01.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Medclair Invest AB's management team is headed by:
- Christer Sjolund - CHM
- Peter Evertsson - CEO
- Roro Yakoub - FDR